Liminal BioSciences development programs target seven transmembrane GPCRs (7TM GPCR’s), where the receptor protein passes through the cell membrane seven times.
These receptors are easily accessible to hydrophilic drugs due to their presence on the cell surface, and their non-uniform expression enables selectivity in modulating physiological processes.
Its drug discovery platform leverages a fully integrated chemistry and biology expertise supported by our broad in vivo capabilities, which allows it to investigate preclinical drug candidates’ efficacy in a wide variety of animal models and enables the Company to develop small molecule therapeutic candidates for the treatment of various metabolic, inflammatory and fibrotic diseases.
In 2023, Liminal BioSciences' updates its goals in its 20-F Filing, which were to leverage its drug discovery platform and to develop distinctive novel small molecule therapeutics to treat the complex biology of metabolic, inflammatory and fibrotic diseases to address a wide range of significant unmet needs.
[7] The company's sought permission from the Toronto Stock Exchange to proceed without a shareholder vote for reasons of "financial hardship".